Current developments in gastric cancer: from molecular profiling to treatment strategy
M Alsina, V Arrazubi, M Diez, J Tabernero - … Reviews Gastroenterology & …, 2023 - nature.com
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
Mapping the genomic diaspora of gastric cancer
Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Y Nakamura, A Kawazoe, F Lordick… - Nature reviews Clinical …, 2021 - nature.com
Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …
targeted and more effective treatments for individual patients with various types of solid …
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …
Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma
PURPOSE The US Food and Drug Administration has granted regulatory approval for the
use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of …
use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of …
Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions
The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies
JI Odegaard, JJ Vincent, S Mortimer, JV Vowles… - Clinical Cancer …, 2018 - AACR
Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase …
Background Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2).
The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether …
The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether …
Predictive biomarkers in gastric cancer
C Röcken - Journal of cancer research and clinical oncology, 2023 - Springer
Predictive biomarkers are the mainstay of precision medicine. This review summarizes the
advancements in tissue-based diagnostic biomarkers for gastric cancer, which is considered …
advancements in tissue-based diagnostic biomarkers for gastric cancer, which is considered …